

# **Pancreatic Cancer Therapeutics & Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other}), By End-User (Hospital & Clinic, Ambulatory Centers, Others) By Region & Competition, 2020-2030F**

<https://marketpublishers.com/r/P809C512A864EN.html>

Date: March 2025

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: P809C512A864EN

## **Abstracts**

Global Pancreatic Cancer Therapeutics & Diagnostics Market was valued at USD 4.60 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 7.50% through 2030. The Global Pancreatic Cancer Therapeutics & Diagnostics Market is a dynamic and evolving sector of the healthcare industry, driven by the urgent need to combat one of the deadliest forms of cancer.

Pancreatic cancer is a relatively rare cancer, accounting for a small percentage of all cancer cases. However, it is one of the most lethal forms of cancer, with a low survival rate. The incidence of pancreatic cancer varies by region, with some areas experiencing higher rates than others. Risk factors include age, family history, smoking, obesity, and certain genetic mutations.

### **Key Market Drivers**

#### **Rising Incidence of Pancreatic Cancer**

The increasing incidence of pancreatic cancer is a major driving force behind the

expansion of the Global Pancreatic Cancer Therapeutics & Diagnostics Market. Pancreatic cancer remains one of the most lethal malignancies, posing a significant challenge to global healthcare systems. In 2020, approximately 500,000 new cases were reported worldwide, with 470,000 fatalities, underscoring the disease's high mortality rate. The global incidence rate stood at 4.9 cases per 100,000 people, while the mortality rate reached 4.5 per 100,000, highlighting the urgent need for more effective diagnostic and therapeutic interventions. This trend is influencing the demand for advanced treatment options, early diagnostic solutions, and improved healthcare infrastructure. Pancreatic cancer is among the most aggressive malignancies, with a high mortality rate. Due to late-stage diagnoses and limited treatment options, the survival rate remains low. The five-year survival rate for pancreatic cancer varies significantly based on the stage at diagnosis. For patients diagnosed at an early, operable stage, the survival rate reaches 20%. However, when considering all cases—including advanced, inoperable stages—the overall five-year survival rate drops to just 5%. The rising number of diagnosed cases worldwide is directly fueling the demand for innovative therapeutic solutions, including chemotherapy, immunotherapy, targeted therapy, and personalized medicine.

## Key Market Challenges

### High Treatment Costs

Pancreatic cancer treatment can be prohibitively expensive. The disease often necessitates aggressive interventions, including surgery, chemotherapy, radiation therapy, and personalized targeted therapies. These treatments not only involve substantial direct medical costs but also indirect costs related to hospitalization, supportive care, and managing side effects. Additionally, the complexity of pancreatic cancer cases often requires specialized healthcare providers and facilities, further driving up costs.

High treatment costs pose financial burdens on patients, healthcare systems, and insurers. This can limit patient access to advanced therapies and diagnostics, impacting market growth. Moreover, it can lead to delays in seeking treatment and influence treatment choices based on cost considerations rather than optimal clinical outcomes.

## Key Market Trends

### Advancements in Personalized Medicine

Personalized medicine is a significant trend in the treatment of pancreatic cancer. This approach tailors treatment plans based on an individual patient's genetic makeup, tumor characteristics, and other factors. Advancements in genomics and molecular profiling technologies have made it possible to identify specific mutations and biomarkers associated with pancreatic cancer. This trend is driven by the need for more effective and targeted therapies, as standard treatments have shown limited success in improving survival rates for pancreatic cancer patients.

The adoption of personalized medicine is expanding the range of therapeutic options available in the market. Pharmaceutical companies are developing targeted therapies that address specific genetic mutations, offering new hope for patients. Diagnostic tools that enable genetic profiling and guide treatment decisions are also in high demand. This trend is expected to drive market growth as more personalized treatment approaches become available.

#### Key Market Players

Myriad Genetics Inc.

Pfizer Inc.

Novartis AG

Bristol-Myers Squibb Company

AstraZeneca PLC

Amgen Inc.

Viatis Inc.

Boston Scientific Corporation

FUJIFILM Holdings Corporation

Canon Inc. (canon Medical Systems Corporation)

Rafael Holdings Inc

## Report Scope:

In this report, the Global Pancreatic Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

### Pancreatic Cancer Therapeutics & Diagnostics Market, By Type:

Treatment

Diagnostics

### Pancreatic Cancer Therapeutics & Diagnostics Market, By End User:

Hospitals & Clinics

Ambulatory Centers

Others

### Pancreatic Cancer Therapeutics & Diagnostics Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Therapeutics & Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

#### Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. VOICE OF CUSTOMER

### 5. PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other})
  - 5.2.2. By End-User (Hospital & Clinic, Ambulatory Centers, Others)
  - 5.2.3. By Region

- 5.2.4. By Company (2024)
- 5.3. Market Map

## **6. NORTH AMERICA PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Type
  - 6.2.2. By End User
  - 6.2.3. By Country
- 6.3. North America: Country Analysis
  - 6.3.1. United States Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
    - 6.3.1.1. Market Size & Forecast
      - 6.3.1.1.1. By Value
    - 6.3.1.2. Market Share & Forecast
      - 6.3.1.2.1. By Type
      - 6.3.1.2.2. By End User
  - 6.3.2. Canada Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
    - 6.3.2.1. Market Size & Forecast
      - 6.3.2.1.1. By Value
    - 6.3.2.2. Market Share & Forecast
      - 6.3.2.2.1. By Type
      - 6.3.2.2.2. By End User
  - 6.3.3. Mexico Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
    - 6.3.3.1. Market Size & Forecast
      - 6.3.3.1.1. By Value
    - 6.3.3.2. Market Share & Forecast
      - 6.3.3.2.1. By Type
      - 6.3.3.2.2. By End User

## **7. EUROPE PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Type



7.2.2. By End User

7.2.3. By Country

### 7.3. Europe: Country Analysis

7.3.1. Germany Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Type

7.3.1.2.2. By End User

7.3.2. United Kingdom Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Type

7.3.2.2.2. By End User

7.3.3. Italy Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Type

7.3.3.2.2. By End User

7.3.4. France Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Type

7.3.4.2.2. By End User

7.3.5. Spain Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Type

7.3.5.2.2. By End User

## **8. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET OUTLOOK**

8.1. Market Size & Forecast

8.1.1. By Value

## 8.2. Market Share & Forecast

### 8.2.1. By Type

### 8.2.2. By End User

### 8.2.3. By Country

## 8.3. Asia-Pacific: Country Analysis

### 8.3.1. China Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 8.3.1.1. Market Size & Forecast

##### 8.3.1.1.1. By Value

#### 8.3.1.2. Market Share & Forecast

##### 8.3.1.2.1. By Type

##### 8.3.1.2.2. By End User

### 8.3.2. India Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 8.3.2.1. Market Size & Forecast

##### 8.3.2.1.1. By Value

#### 8.3.2.2. Market Share & Forecast

##### 8.3.2.2.1. By Type

##### 8.3.2.2.2. By End User

### 8.3.3. Japan Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 8.3.3.1. Market Size & Forecast

##### 8.3.3.1.1. By Value

#### 8.3.3.2. Market Share & Forecast

##### 8.3.3.2.1. By Type

##### 8.3.3.2.2. By End User

### 8.3.4. South Korea Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 8.3.4.1. Market Size & Forecast

##### 8.3.4.1.1. By Value

#### 8.3.4.2. Market Share & Forecast

##### 8.3.4.2.1. By Type

##### 8.3.4.2.2. By End User

### 8.3.5. Australia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 8.3.5.1. Market Size & Forecast

##### 8.3.5.1.1. By Value

#### 8.3.5.2. Market Share & Forecast

##### 8.3.5.2.1. By Type

##### 8.3.5.2.2. By End User

## **9. SOUTH AMERICA PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET OUTLOOK**

## 9.1. Market Size & Forecast

### 9.1.1. By Value

## 9.2. Market Share & Forecast

### 9.2.1. By Type

### 9.2.2. By End User

### 9.2.3. By Country

## 9.3. South America: Country Analysis

### 9.3.1. Brazil Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 9.3.1.1. Market Size & Forecast

##### 9.3.1.1.1. By Value

#### 9.3.1.2. Market Share & Forecast

##### 9.3.1.2.1. By Type

##### 9.3.1.2.2. By End User

### 9.3.2. Argentina Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 9.3.2.1. Market Size & Forecast

##### 9.3.2.1.1. By Value

#### 9.3.2.2. Market Share & Forecast

##### 9.3.2.2.1. By Type

##### 9.3.2.2.2. By End User

### 9.3.3. Colombia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 9.3.3.1. Market Size & Forecast

##### 9.3.3.1.1. By Value

#### 9.3.3.2. Market Share & Forecast

##### 9.3.3.2.1. By Type

##### 9.3.3.2.2. By End User

## **10. MIDDLE EAST AND AFRICA PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET OUTLOOK**

## 10.1. Market Size & Forecast

### 10.1.1. By Value

## 10.2. Market Share & Forecast

### 10.2.1. By Type

### 10.2.2. By End User

### 10.2.3. By Country

## 10.3. MEA: Country Analysis

### 10.3.1. South Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

#### 10.3.1.1. Market Size & Forecast

##### 10.3.1.1.1. By Value

- 10.3.1.2. Market Share & Forecast
  - 10.3.1.2.1. By Type
  - 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By End User
- 10.3.3. UAE Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By End User

## **11. MARKET DYNAMICS**

- 11.1. Drivers
- 11.2. Challenges

## **12. MARKET TRENDS & DEVELOPMENTS**

- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions

## **13. GLOBAL PANCREATIC CANCER THERAPEUTICS & DIAGNOSTICS MARKET: SWOT ANALYSIS**

## **14. COMPETITIVE LANDSCAPE**

- 14.1. Myriad Genetics Inc.
  - 14.1.1. Business Overview
  - 14.1.2. Product & Service Offerings
  - 14.1.3. Recent Developments
  - 14.1.4. Financials (If Listed)
  - 14.1.5. Key Personnel
  - 14.1.6. SWOT Analysis

- 14.2. Pfizer Inc.
- 14.3. Novartis AG
- 14.4. Bristol-Myers Squibb Company
- 14.5. AstraZeneca PLC
- 14.6. Amgen Inc.
- 14.7. Viatris Inc.
- 14.8. Boston Scientific Corporation
- 14.9. FUJIFILM Holdings Corporation
- 14.10. Canon Inc. (Canon Medical Systems Corporation)
- 14.11. Rafael Holdings Inc.

## **15. STRATEGIC RECOMMENDATIONS**

## **16. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Pancreatic Cancer Therapeutics & Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other}), By End-User (Hospital & Clinic, Ambulatory Centers, Others) By Region & Competition, 2020-2030F

Product link: <https://marketpublishers.com/r/P809C512A864EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P809C512A864EN.html>